News Release

IHMT-CSF1R-833 discovered as potent and selective CSF1R inhibitor

Peer-Reviewed Publication

Hefei Institutes of Physical Science, Chinese Academy of Sciences

IHMT-CSF1R-833 Discovered as Potent and Selective CSF1R Inhibitor

image: IHMT-CSF1R-833 alters the macrophage polarization in M2 macrophages derived from RAW264.7 cells by inducing the M1 macrophage phenotype. view more 

Credit: LIANG Xiaofei

Recently, a potent and selective colony stimulating factor 1 receptor kinase inhibitor IHMT-CSF1R-833 was discovered by the team led by Prof. LIU Qingsong from Hefei Institutes of Physical Science (HFIPS), Chinese Academy of Sciences.

Colony stimulating factor 1 receptor (CSF1R) belongs to the type III growth factor receptor family. CSF1R signaling is crucial for the differentiation and survival of macrophages and plays integral roles in the tumor promoting and immune suppressive functions of tumor-associated macrophage. Suppression of tumor-associated macrophage survival/activation by inhibiting CSF1R signaling becomes a highly attractive strategy for cancer immunotherapy.

Most of the current CSF1R inhibitors lack proper selectivity among other kinases, and thus it is difficult to correlate their therapeutic efficacies with CSF1R inhibition. Therefore, it is still highly desirable to identify the distinct chemical scaffolds CSF1R inhibitors for both the preclinical mechanistic and clinical pathological studies.

In this study, the researchers reported a potent and selective CSF1R inhibitor IHMT-CSF1R-833 using a focused medicinal chemistry approach guided by computer-aided drug design.

IHMT-CSF1R-833 exhibited potent inhibitory activity against CSF1R with an IC50 value of 5.14 nM, suppressing the phosphorylation of CSF1R and its downstream signals pathway in a dose-dependent manner.

Meanwhile, it showed high selectivity over a broad range of human kinases. Furthermore, IHMT-CSF1R-833 repolarized M2 macrophages to M1 macrophages in RAW264.7 macrophages in a dose-dependent manner.

In vivo, IHMT-CSF1R-833 demonstrated acceptable pharmacokinetic properties for oral administration in rats and exhibited dose-dependent antitumor efficacies in the M-NFS-60 tumor xenograft model.

These results indicated that IHMT-CSF1R-833 might be a valuable research tool for the CSF1R-mediated macrophage in both the preclinical mechanistic and clinical pathological studies.

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.